Compare · BCAX vs NVO
BCAX vs NVO
Side-by-side comparison of Bicara Therapeutics Inc. (BCAX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BCAX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 138.7x BCAX ($1.32B).
- Over the past year, BCAX is up 76.4% and NVO is down 45.7% - BCAX leads by 122.0 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 6 for BCAX).
- NVO has more recent analyst coverage (25 ratings vs 15 for BCAX).
- Company
- Bicara Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $20.11+0.53%
- $41.01-4.51%
- Market cap
- $1.32B
- $183.15B
- 1M return
- -12.95%
- -10.44%
- 1Y return
- +76.36%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 6
- 8
- Recent ratings
- 15
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BCAX
- SEC Form 144 filed by Bicara Therapeutics Inc.
- Chief Financial Officer Hyep Ivan exercised 9,200 shares at a strike of $3.79 and sold $187,883 worth of shares (9,200 units at $20.42) as part of a pre-agreed trading plan (SEC Form 4)
- Bicara Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
- Chief Executive Officer Mazumdar Claire exercised 15,000 shares at a strike of $3.79 and sold $300,579 worth of shares (15,000 units at $20.04) as part of a pre-agreed trading plan (SEC Form 4)
- President and COO Cohlhepp Ryan exercised 8,000 shares at a strike of $3.79 and sold $253,649 worth of shares (12,500 units at $20.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 191,641 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Bicara Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Bicara Therapeutics Inc.
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care